|
- 积分
- 299
- 威望
- 299
- 包包
- 1702
|
Mol Ther. 2011 Mar;19(3):584-93. Epub 2010 Nov 30.: H8 n- B% }$ ~
9 e* u4 c5 [& E$ p, P: r" `5 J/ [
Generation of HIV-1 Resistant and Functional Macrophages From Hematopoietic Stem Cell-derived Induced Pluripotent Stem Cells.
0 H, O( r4 c1 Q1 bKambal A, Mitchell G, Cary W, Gruenloh W, Jung Y, Kalomoiris S, Nacey C, McGee J, Lindsey M, Fury B, Bauer G, Nolta JA, Anderson JS.
- S+ q1 s h7 ?" k w9 V4 O o
7 ?+ }' y1 F' ^Stem Cell Program, Department of Internal Medicine, University of California, Davis, Sacramento, California, USA.! T. g: _8 p Z4 l! T
& |+ y3 T! Q/ O% P7 eAbstract
) _0 y9 J9 K3 k. u- GInduced pluripotent stem cells (iPSCs) have radically advanced the field of regenerative medicine by making possible the production of patient-specific pluripotent stem cells from adult individuals. By developing iPSCs to treat HIV, there is the potential for generating a continuous supply of therapeutic cells for transplantation into HIV-infected patients. In this study, we have used human hematopoietic stem cells (HSCs) to generate anti-HIV gene expressing iPSCs for HIV gene therapy. HSCs were dedifferentiated into continuously growing iPSC lines with four reprogramming factors and a combination anti-HIV lentiviral vector containing a CCR5 short hairpin RNA (shRNA) and a human/rhesus chimeric TRIM5α gene. Upon directed differentiation of the anti-HIV iPSCs toward the hematopoietic lineage, a robust quantity of colony-forming CD133(+) HSCs were obtained. These cells were further differentiated into functional end-stage macrophages which displayed a normal phenotypic profile. Upon viral challenge, the anti-HIV iPSC-derived macrophages exhibited strong protection from HIV-1 infection. Here, we demonstrate the ability of iPSCs to develop into HIV-1 resistant immune cells and highlight the potential use of iPSCs for HIV gene and cellular therapies.$ V: u# W+ z \
4 j: m1 ?" h2 ]" v( x& S
|
-
总评分: 威望 + 2
包包 + 5
查看全部评分
|
发表于 2011-3-24 15:13
